SCHEMBL29655732

SCHEMBL29655732

[2H]C1CC12CCOc1ccc(C(=O)NC3CCCC3)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.62
RAB9A P51151 7/20 0.62
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 2/20 0.55
TP53 P04637 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
CNR2 P34972 2/20 0.52
ACHE P22303 1/20 0.46
TSHR P16473 2/20 0.46
PTGER4 P35408 2/20 0.46
GAA P10253 1/20 0.46
MAPK11 Q15759 1/20 0.45
MAPK14 Q16539 1/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655717 0.90 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HPGDTP53
SCHEMBL29655774 0.88 NPC1 (0.56) NPC1RAB9ASMN1; SMN2HPGDTP53
SCHEMBL31743230 0.84 NPC1 (0.53) NPC1RAB9ASMN1; SMN2HPGDTP53
SCHEMBL29655785 0.81 CYP26A1 (0.46) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL29655544 0.79 PTGER4 (0.46) NPC1RAB9ASMN1; SMN2HPGDTP53
SCHEMBL29696137 0.73 CYP26A1 (0.47) NPC1RAB9ASMN1; SMN2HPGDNFKB1
SCHEMBL29655815 0.73 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2PTGER4GAA
SCHEMBL29655794 0.72 MAPK14 (0.45) RAB9AHPGDMAPK11MAPK14KMT2A
SCHEMBL30353220 0.72 RARA (0.54) NPC1RAB9ATSHRALDH1A1
SCHEMBL28347731 0.72 RARA (0.54) NPC1RAB9ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022138793-A1 COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST 小野薬品工業株式会社 2022-06-30 WO disclosed
WO-2022102731-A1 CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR 小野薬品工業株式会社 2022-05-19 WO disclosed